Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Cosmo Pharmaceuticals
Deal Size : $63.5 million
Deal Type : Licensing Agreement
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Details : Under the terms of the License agreement, 3SBio will receive from Cosmo the exclusive right to develop and commercialize Winlevi (clascoterone) in Greater China, which is indicated for acne vulgaris.
Brand Name : Winlevi
Molecule Type : Small molecule
Upfront Cash : $6.5 million
July 28, 2022
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Cosmo Pharmaceuticals
Deal Size : $63.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Anti-VSIG4 antibodies
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Verseau Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Sunshine Guojian received an exclusive license to develop and commercialize a select number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : Anti-VSIG4 antibodies
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Verseau Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pegadricase
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Details : Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.
Brand Name : SEL-212
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Pegadricase
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
